Oligonucleotides for reduction of pd-l1 expression
AssigneeHoffmann-La Roche Inc.
InventorsLykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
Claims1
An antisense oligonucleotide conjugate of formula GN2-C6oco aoCCtatttaacatcAGAC, wherein C6 represents an amino alkyl group with 6 carbons, capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, subscript o represent a phosphodiester nucleoside linkage and all other internucleoside linkages are phosphorothioate internucleoside linkages, and wherein GN2 represents the trivalent GalNAc cluster of formula
- wherein the wavy line illustrates the site of conjugation of the cluster to the a C6 amino linker.
Dependencies are inferred from the claim text.